Francis Ndungu/Wellcome Open Res


4 results

Safety and immunogenicity of varied doses of R21/Matrix-Mâ„¢ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.Sang S, Datoo MS, Otieno E, Muiruri C, Bellamy D, Gathuri E, Ngoto O, Musembi J, Provstgaard-Morys S, Stockdale L, Aboagye J, Woods D, Lawrie A, Roberts R, Keter K, Kimani D, Ndungu F, Kapulu M, Njau I, Orindi B, Ewer KJ, Hill AVS, Bejon P, Hamaluba M
Wellcome Open Res, (2023). 8:450

TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults).Abouyannis M, FitzGerald R, Ngama M, Mwangudzah H, Nyambura YK, Ngome S, Riako D, Babu L, Lewa F, Else L, Dily Penchala S, Orindi B, Mumba N, Kalama B, Ndungu FM, Adetifa I, Khoo S, Lalloo DG, Casewell NR, Hamaluba M
Wellcome Open Res, (2022). 7:90

10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity.Addy JWG, Bediako Y, Ndungu FM, Valetta JJ, Reid AJ, Mwacharo J, Ngoi JM, Wambua J, Otieno E, Musyoki J, Said K, Berriman M, Marsh K, Bejon P, Recker M, Langhorne J
Wellcome Open Res, (2021). 6:79

A seven-year study on the effect of the pre-erythrocytic malaria vaccine candidate RTS,S/AS01 E on blood stage immunity in young Kenyan children.Ndungu FM, Mwacharo J, Wambua J, Njuguna P, Marsh K, Drakeley C, Bejon P
Wellcome Open Res, (2019). 4:42